phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with Cardiovascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrzejewski, K; Kaczyńska, K; Wojciechowski, P | 1 |
| Chazov, EI | 1 |
2 other study(ies) available for phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and Cardiovascular Diseases
| Article | Year |
|---|---|
Intracerebroventricular Neuropeptide FF Diminishes the Number of Apneas and Cardiovascular Effects Produced by Opioid Receptors' Activation.
Topics: Analgesia; Analgesics, Opioid; Animals; Apnea; Cardiovascular Diseases; Disease Models, Animal; Humans; Infusions, Intraventricular; Oligopeptides; Pain Perception; Rats; Receptors, Neuropeptide; Receptors, Opioid, mu; Transcriptional Activation | 2020 |
[Progress in fundamental research: perspectives of cardiology].
Topics: Apelin; Biomarkers; Cardiology; Cardiovascular Diseases; Endothelium, Vascular; Humans; Intercellular Signaling Peptides and Proteins; Malondialdehyde; Nitric Oxide; Oligopeptides; Pyruvaldehyde; Receptors, Neuropeptide; Russia | 2009 |